Cooley advised biotechnology company Cidara Therapeutics on its exclusive worldwide licensing and collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of seasonal and pandemic influenza. Partners Jane Adams and Tanisha James led the Cooley team advising Cidara.
Under the terms of the collaboration, Cidara will be responsible for the development and manufacturing of the first influenza antiviral conjugates, CD388, into the clinic and through phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. Cidara will receive a $27 million upfront payment and will be eligible to receive up to $753 million in budgeted research and development funding and in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales.
